ORY — ORYZON Genomics SA Income Statement
0.000.00%
Last trade - 00:00- €265.74m
- €248.35m
- 11
- 22
- 81
- 27
Annual income statement for ORYZON Genomics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | -0.683 | -3.2 | -2.38 | -1.14 | -1.01 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.29 | 7.01 | 5.49 | 4.55 | 4.42 |
| Operating Profit | -4.29 | -7.01 | -5.49 | -4.55 | -4.42 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -4.78 | -7.18 | -6.56 | -6.1 | -5.57 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.4 | -4.69 | -4.23 | -3.35 | -3.67 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.4 | -4.69 | -4.23 | -3.35 | -3.67 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.4 | -4.69 | -4.23 | -3.35 | -3.67 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.064 | -0.089 | -0.077 | -0.055 | -0.057 |
| Dividends per Share |